nodes	percent_of_prediction	percent_of_DWPC	metapath
Pitavastatin—UGT2B7—Mycophenolic acid—psoriasis	0.102	0.121	CbGbCtD
Pitavastatin—SLC10A1—Cyclosporine—psoriasis	0.0901	0.107	CbGbCtD
Pitavastatin—SLCO1B3—Mycophenolate mofetil—psoriasis	0.0587	0.0696	CbGbCtD
Pitavastatin—UGT2B7—Mycophenolate mofetil—psoriasis	0.0571	0.0677	CbGbCtD
Pitavastatin—ALB—Acitretin—psoriasis	0.04	0.0474	CbGbCtD
Pitavastatin—CYP2C8—Tazarotene—psoriasis	0.0391	0.0463	CbGbCtD
Pitavastatin—SLCO1B1—Mycophenolate mofetil—psoriasis	0.0342	0.0405	CbGbCtD
Pitavastatin—ABCC2—Mycophenolate mofetil—psoriasis	0.03	0.0356	CbGbCtD
Pitavastatin—ABCG2—Mycophenolate mofetil—psoriasis	0.0272	0.0322	CbGbCtD
Pitavastatin—SLCO1B1—Cyclosporine—psoriasis	0.0259	0.0307	CbGbCtD
Pitavastatin—SLCO1B3—Methotrexate—psoriasis	0.0235	0.0279	CbGbCtD
Pitavastatin—ABCC2—Cyclosporine—psoriasis	0.0228	0.027	CbGbCtD
Pitavastatin—ABCG2—Hydrocortisone—psoriasis	0.0218	0.0258	CbGbCtD
Pitavastatin—ABCG2—Cyclosporine—psoriasis	0.0206	0.0244	CbGbCtD
Pitavastatin—ALB—Mycophenolate mofetil—psoriasis	0.0187	0.0222	CbGbCtD
Pitavastatin—CYP2C8—Cholecalciferol—psoriasis	0.0167	0.0198	CbGbCtD
Pitavastatin—ABCC2—Dexamethasone—psoriasis	0.015	0.0178	CbGbCtD
Pitavastatin—ALB—Prednisone—psoriasis	0.015	0.0177	CbGbCtD
Pitavastatin—CYP2C8—Mycophenolate mofetil—psoriasis	0.0145	0.0172	CbGbCtD
Pitavastatin—SLCO1B1—Methotrexate—psoriasis	0.0137	0.0163	CbGbCtD
Pitavastatin—ABCG2—Dexamethasone—psoriasis	0.0136	0.0161	CbGbCtD
Pitavastatin—ABCC2—Methotrexate—psoriasis	0.0121	0.0143	CbGbCtD
Pitavastatin—CYP2C9—Cholecalciferol—psoriasis	0.0116	0.0138	CbGbCtD
Pitavastatin—CYP2C8—Hydrocortisone—psoriasis	0.0116	0.0138	CbGbCtD
Pitavastatin—CYP2C8—Cyclosporine—psoriasis	0.011	0.013	CbGbCtD
Pitavastatin—ABCG2—Methotrexate—psoriasis	0.0109	0.0129	CbGbCtD
Pitavastatin—ABCB1—Mycophenolate mofetil—psoriasis	0.0098	0.0116	CbGbCtD
Pitavastatin—ABCB1—Betamethasone—psoriasis	0.0084	0.00996	CbGbCtD
Pitavastatin—ABCB1—Prednisolone—psoriasis	0.00829	0.00983	CbGbCtD
Pitavastatin—ABCB1—Hydrocortisone—psoriasis	0.00786	0.00932	CbGbCtD
Pitavastatin—ABCB1—Prednisone—psoriasis	0.00783	0.00928	CbGbCtD
Pitavastatin—CYP2C9—Cyclosporine—psoriasis	0.00765	0.00907	CbGbCtD
Pitavastatin—ALB—Methotrexate—psoriasis	0.00751	0.0089	CbGbCtD
Pitavastatin—ABCB1—Cyclosporine—psoriasis	0.00742	0.0088	CbGbCtD
Pitavastatin—CYP2C8—Dexamethasone—psoriasis	0.00722	0.00856	CbGbCtD
Pitavastatin—CYP2C9—Dexamethasone—psoriasis	0.00504	0.00597	CbGbCtD
Pitavastatin—ABCB1—Dexamethasone—psoriasis	0.00489	0.00579	CbGbCtD
Pitavastatin—ABCB1—Methotrexate—psoriasis	0.00393	0.00466	CbGbCtD
Pitavastatin—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.000833	0.0509	CbGpPWpGaD
Pitavastatin—SLC10A1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000709	0.0433	CbGpPWpGaD
Pitavastatin—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000678	0.0414	CbGpPWpGaD
Pitavastatin—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000516	0.0316	CbGpPWpGaD
Pitavastatin—HMGCR—Activation of gene expression by SREBF (SREBP)—CARM1—psoriasis	0.000488	0.0298	CbGpPWpGaD
Pitavastatin—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.00042	0.0257	CbGpPWpGaD
Pitavastatin—HMGCR—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CARM1—psoriasis	0.00039	0.0238	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—IL22—psoriasis	0.000361	0.0221	CbGpPWpGaD
Pitavastatin—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.000333	0.00238	CcSEcCtD
Pitavastatin—Hepatitis—Mycophenolate mofetil—psoriasis	0.000331	0.00237	CcSEcCtD
Pitavastatin—Hypoaesthesia—Mycophenolate mofetil—psoriasis	0.00033	0.00236	CcSEcCtD
Pitavastatin—Malaise—Mycophenolic acid—psoriasis	0.00033	0.00236	CcSEcCtD
Pitavastatin—Asthenia—Acitretin—psoriasis	0.000325	0.00233	CcSEcCtD
Pitavastatin—Rash—Calcitriol—psoriasis	0.000322	0.0023	CcSEcCtD
Pitavastatin—Dermatitis—Calcitriol—psoriasis	0.000321	0.0023	CcSEcCtD
Pitavastatin—Pruritus—Acitretin—psoriasis	0.000321	0.00229	CcSEcCtD
Pitavastatin—Pruritus—Fluocinolone Acetonide—psoriasis	0.00032	0.00229	CcSEcCtD
Pitavastatin—Headache—Calcitriol—psoriasis	0.000319	0.00228	CcSEcCtD
Pitavastatin—ABCC2—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000318	0.0194	CbGpPWpGaD
Pitavastatin—Dyspepsia—Hydroxyurea—psoriasis	0.000314	0.00224	CcSEcCtD
Pitavastatin—Myalgia—Mycophenolic acid—psoriasis	0.000311	0.00222	CcSEcCtD
Pitavastatin—Arthralgia—Mycophenolic acid—psoriasis	0.000311	0.00222	CcSEcCtD
Pitavastatin—Diarrhoea—Acitretin—psoriasis	0.00031	0.00222	CcSEcCtD
Pitavastatin—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00031	0.00221	CcSEcCtD
Pitavastatin—Discomfort—Mycophenolic acid—psoriasis	0.000307	0.0022	CcSEcCtD
Pitavastatin—Fatigue—Hydroxyurea—psoriasis	0.000307	0.00219	CcSEcCtD
Pitavastatin—Constipation—Hydroxyurea—psoriasis	0.000305	0.00218	CcSEcCtD
Pitavastatin—Nausea—Calcitriol—psoriasis	0.000303	0.00216	CcSEcCtD
Pitavastatin—Hepatic failure—Methotrexate—psoriasis	0.000302	0.00216	CcSEcCtD
Pitavastatin—HMGCR—Statin Pathway—APOE—psoriasis	0.000302	0.0184	CbGpPWpGaD
Pitavastatin—Confusional state—Mycophenolic acid—psoriasis	0.000301	0.00215	CcSEcCtD
Pitavastatin—Dizziness—Acitretin—psoriasis	0.0003	0.00214	CcSEcCtD
Pitavastatin—Dizziness—Fluocinolone Acetonide—psoriasis	0.000299	0.00214	CcSEcCtD
Pitavastatin—SLCO1B1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000298	0.0182	CbGpPWpGaD
Pitavastatin—Renal failure acute—Methotrexate—psoriasis	0.000294	0.0021	CcSEcCtD
Pitavastatin—Feeling abnormal—Hydroxyurea—psoriasis	0.000293	0.0021	CcSEcCtD
Pitavastatin—Rash—Acitretin—psoriasis	0.000286	0.00204	CcSEcCtD
Pitavastatin—Dermatitis—Acitretin—psoriasis	0.000286	0.00204	CcSEcCtD
Pitavastatin—Rash—Fluocinolone Acetonide—psoriasis	0.000285	0.00204	CcSEcCtD
Pitavastatin—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000285	0.00204	CcSEcCtD
Pitavastatin—Muscle spasms—Cyclosporine—psoriasis	0.000284	0.00203	CcSEcCtD
Pitavastatin—Headache—Acitretin—psoriasis	0.000284	0.00203	CcSEcCtD
Pitavastatin—Headache—Fluocinolone Acetonide—psoriasis	0.000283	0.00203	CcSEcCtD
Pitavastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000283	0.0173	CbGpPWpGaD
Pitavastatin—Back pain—Mycophenolate mofetil—psoriasis	0.000279	0.00199	CcSEcCtD
Pitavastatin—Muscle spasms—Mycophenolate mofetil—psoriasis	0.000277	0.00198	CcSEcCtD
Pitavastatin—Ill-defined disorder—Cyclosporine—psoriasis	0.000274	0.00196	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000272	0.00194	CcSEcCtD
Pitavastatin—Insomnia—Mycophenolic acid—psoriasis	0.00027	0.00193	CcSEcCtD
Pitavastatin—Nausea—Acitretin—psoriasis	0.000269	0.00193	CcSEcCtD
Pitavastatin—Nausea—Fluocinolone Acetonide—psoriasis	0.000269	0.00192	CcSEcCtD
Pitavastatin—Ill-defined disorder—Mycophenolate mofetil—psoriasis	0.000268	0.00191	CcSEcCtD
Pitavastatin—Malaise—Cyclosporine—psoriasis	0.000267	0.00191	CcSEcCtD
Pitavastatin—Dyspepsia—Mycophenolic acid—psoriasis	0.000263	0.00188	CcSEcCtD
Pitavastatin—Hypersensitivity—Hydroxyurea—psoriasis	0.000262	0.00188	CcSEcCtD
Pitavastatin—HMGCR—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000262	0.016	CbGpPWpGaD
Pitavastatin—Malaise—Mycophenolate mofetil—psoriasis	0.00026	0.00186	CcSEcCtD
Pitavastatin—Erectile dysfunction—Prednisone—psoriasis	0.000258	0.00185	CcSEcCtD
Pitavastatin—Fatigue—Mycophenolic acid—psoriasis	0.000257	0.00184	CcSEcCtD
Pitavastatin—Asthenia—Hydroxyurea—psoriasis	0.000256	0.00183	CcSEcCtD
Pitavastatin—Constipation—Mycophenolic acid—psoriasis	0.000255	0.00182	CcSEcCtD
Pitavastatin—UGT1A3—Biological oxidations—CYP2S1—psoriasis	0.000254	0.0155	CbGpPWpGaD
Pitavastatin—Myalgia—Cyclosporine—psoriasis	0.000252	0.0018	CcSEcCtD
Pitavastatin—Arthralgia—Cyclosporine—psoriasis	0.000252	0.0018	CcSEcCtD
Pitavastatin—UGT1A3—Metapathway biotransformation—CYP2S1—psoriasis	0.00025	0.0153	CbGpPWpGaD
Pitavastatin—Ill-defined disorder—Prednisolone—psoriasis	0.00025	0.00178	CcSEcCtD
Pitavastatin—Discomfort—Cyclosporine—psoriasis	0.000249	0.00178	CcSEcCtD
Pitavastatin—Feeling abnormal—Mycophenolic acid—psoriasis	0.000246	0.00176	CcSEcCtD
Pitavastatin—Myalgia—Mycophenolate mofetil—psoriasis	0.000246	0.00176	CcSEcCtD
Pitavastatin—Arthralgia—Mycophenolate mofetil—psoriasis	0.000246	0.00176	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000244	0.00174	CcSEcCtD
Pitavastatin—Ill-defined disorder—Hydrocortisone—psoriasis	0.000244	0.00174	CcSEcCtD
Pitavastatin—Diarrhoea—Hydroxyurea—psoriasis	0.000244	0.00174	CcSEcCtD
Pitavastatin—Confusional state—Cyclosporine—psoriasis	0.000243	0.00174	CcSEcCtD
Pitavastatin—Malaise—Prednisolone—psoriasis	0.000243	0.00173	CcSEcCtD
Pitavastatin—Discomfort—Mycophenolate mofetil—psoriasis	0.000243	0.00173	CcSEcCtD
Pitavastatin—Back pain—Triamcinolone—psoriasis	0.000239	0.00171	CcSEcCtD
Pitavastatin—Confusional state—Mycophenolate mofetil—psoriasis	0.000237	0.0017	CcSEcCtD
Pitavastatin—Malaise—Hydrocortisone—psoriasis	0.000237	0.00169	CcSEcCtD
Pitavastatin—Abdominal pain—Mycophenolic acid—psoriasis	0.000236	0.00169	CcSEcCtD
Pitavastatin—Dizziness—Hydroxyurea—psoriasis	0.000236	0.00168	CcSEcCtD
Pitavastatin—ABCG2—Iron uptake and transport—CP—psoriasis	0.000231	0.0141	CbGpPWpGaD
Pitavastatin—Ill-defined disorder—Triamcinolone—psoriasis	0.00023	0.00164	CcSEcCtD
Pitavastatin—Discomfort—Prednisolone—psoriasis	0.000226	0.00162	CcSEcCtD
Pitavastatin—Abdominal discomfort—Methotrexate—psoriasis	0.000225	0.00161	CcSEcCtD
Pitavastatin—Rash—Hydroxyurea—psoriasis	0.000225	0.00161	CcSEcCtD
Pitavastatin—Dermatitis—Hydroxyurea—psoriasis	0.000224	0.0016	CcSEcCtD
Pitavastatin—Myalgia—Hydrocortisone—psoriasis	0.000224	0.0016	CcSEcCtD
Pitavastatin—Malaise—Triamcinolone—psoriasis	0.000223	0.00159	CcSEcCtD
Pitavastatin—Headache—Hydroxyurea—psoriasis	0.000223	0.00159	CcSEcCtD
Pitavastatin—Discomfort—Hydrocortisone—psoriasis	0.000221	0.00158	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.00022	0.00157	CcSEcCtD
Pitavastatin—Insomnia—Cyclosporine—psoriasis	0.000218	0.00156	CcSEcCtD
Pitavastatin—HMGCR—PPARA activates gene expression—CARM1—psoriasis	0.000217	0.0133	CbGpPWpGaD
Pitavastatin—Erectile dysfunction—Methotrexate—psoriasis	0.000216	0.00154	CcSEcCtD
Pitavastatin—UGT2B7—Biological oxidations—CYP2S1—psoriasis	0.000216	0.0132	CbGpPWpGaD
Pitavastatin—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000214	0.00153	CcSEcCtD
Pitavastatin—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000214	0.0131	CbGpPWpGaD
Pitavastatin—Asthenia—Mycophenolic acid—psoriasis	0.000214	0.00153	CcSEcCtD
Pitavastatin—Insomnia—Mycophenolate mofetil—psoriasis	0.000213	0.00152	CcSEcCtD
Pitavastatin—UGT2B7—Metapathway biotransformation—CYP2S1—psoriasis	0.000213	0.013	CbGpPWpGaD
Pitavastatin—HMGCR—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000213	0.013	CbGpPWpGaD
Pitavastatin—Dyspepsia—Cyclosporine—psoriasis	0.000212	0.00152	CcSEcCtD
Pitavastatin—Nausea—Hydroxyurea—psoriasis	0.000212	0.00151	CcSEcCtD
Pitavastatin—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000212	0.0129	CbGpPWpGaD
Pitavastatin—Pruritus—Mycophenolic acid—psoriasis	0.000211	0.00151	CcSEcCtD
Pitavastatin—Myalgia—Triamcinolone—psoriasis	0.000211	0.00151	CcSEcCtD
Pitavastatin—Ill-defined disorder—Dexamethasone—psoriasis	0.000208	0.00149	CcSEcCtD
Pitavastatin—Ill-defined disorder—Betamethasone—psoriasis	0.000208	0.00149	CcSEcCtD
Pitavastatin—Discomfort—Triamcinolone—psoriasis	0.000208	0.00149	CcSEcCtD
Pitavastatin—Fatigue—Cyclosporine—psoriasis	0.000208	0.00149	CcSEcCtD
Pitavastatin—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000207	0.00148	CcSEcCtD
Pitavastatin—Constipation—Cyclosporine—psoriasis	0.000206	0.00148	CcSEcCtD
Pitavastatin—Diarrhoea—Mycophenolic acid—psoriasis	0.000204	0.00146	CcSEcCtD
Pitavastatin—Malaise—Dexamethasone—psoriasis	0.000202	0.00145	CcSEcCtD
Pitavastatin—Malaise—Betamethasone—psoriasis	0.000202	0.00145	CcSEcCtD
Pitavastatin—Constipation—Mycophenolate mofetil—psoriasis	0.000201	0.00144	CcSEcCtD
Pitavastatin—Feeling abnormal—Cyclosporine—psoriasis	0.000199	0.00142	CcSEcCtD
Pitavastatin—Insomnia—Prednisolone—psoriasis	0.000199	0.00142	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Cyclosporine—psoriasis	0.000197	0.00141	CcSEcCtD
Pitavastatin—Dizziness—Mycophenolic acid—psoriasis	0.000197	0.00141	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000195	0.0014	CcSEcCtD
Pitavastatin—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000194	0.00139	CcSEcCtD
Pitavastatin—Insomnia—Hydrocortisone—psoriasis	0.000194	0.00139	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000192	0.00138	CcSEcCtD
Pitavastatin—Urticaria—Cyclosporine—psoriasis	0.000192	0.00137	CcSEcCtD
Pitavastatin—Myalgia—Dexamethasone—psoriasis	0.000191	0.00137	CcSEcCtD
Pitavastatin—Myalgia—Betamethasone—psoriasis	0.000191	0.00137	CcSEcCtD
Pitavastatin—Abdominal pain—Cyclosporine—psoriasis	0.000191	0.00136	CcSEcCtD
Pitavastatin—Discomfort—Dexamethasone—psoriasis	0.000189	0.00135	CcSEcCtD
Pitavastatin—Discomfort—Betamethasone—psoriasis	0.000189	0.00135	CcSEcCtD
Pitavastatin—Dyspepsia—Hydrocortisone—psoriasis	0.000189	0.00135	CcSEcCtD
Pitavastatin—Rash—Mycophenolic acid—psoriasis	0.000188	0.00134	CcSEcCtD
Pitavastatin—Dermatitis—Mycophenolic acid—psoriasis	0.000188	0.00134	CcSEcCtD
Pitavastatin—Hepatitis—Methotrexate—psoriasis	0.000188	0.00134	CcSEcCtD
Pitavastatin—Urticaria—Mycophenolate mofetil—psoriasis	0.000187	0.00134	CcSEcCtD
Pitavastatin—Headache—Mycophenolic acid—psoriasis	0.000187	0.00134	CcSEcCtD
Pitavastatin—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000186	0.00133	CcSEcCtD
Pitavastatin—Fatigue—Hydrocortisone—psoriasis	0.000185	0.00132	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000184	0.00132	CcSEcCtD
Pitavastatin—Insomnia—Triamcinolone—psoriasis	0.000183	0.00131	CcSEcCtD
Pitavastatin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000182	0.0112	CbGpPWpGaD
Pitavastatin—Ill-defined disorder—Prednisone—psoriasis	0.000181	0.0013	CcSEcCtD
Pitavastatin—Feeling abnormal—Prednisolone—psoriasis	0.000181	0.00129	CcSEcCtD
Pitavastatin—Hypersensitivity—Cyclosporine—psoriasis	0.000178	0.00127	CcSEcCtD
Pitavastatin—Dyspepsia—Triamcinolone—psoriasis	0.000178	0.00127	CcSEcCtD
Pitavastatin—Nausea—Mycophenolic acid—psoriasis	0.000177	0.00127	CcSEcCtD
Pitavastatin—Feeling abnormal—Hydrocortisone—psoriasis	0.000177	0.00126	CcSEcCtD
Pitavastatin—Malaise—Prednisone—psoriasis	0.000176	0.00126	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000175	0.00125	CcSEcCtD
Pitavastatin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000174	0.0107	CbGpPWpGaD
Pitavastatin—Urticaria—Prednisolone—psoriasis	0.000174	0.00125	CcSEcCtD
Pitavastatin—Fatigue—Triamcinolone—psoriasis	0.000174	0.00124	CcSEcCtD
Pitavastatin—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000174	0.0106	CbGpPWpGaD
Pitavastatin—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000173	0.00124	CcSEcCtD
Pitavastatin—Asthenia—Cyclosporine—psoriasis	0.000173	0.00124	CcSEcCtD
Pitavastatin—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000172	0.0105	CbGpPWpGaD
Pitavastatin—Pruritus—Cyclosporine—psoriasis	0.000171	0.00122	CcSEcCtD
Pitavastatin—Urticaria—Hydrocortisone—psoriasis	0.00017	0.00122	CcSEcCtD
Pitavastatin—Abdominal pain—Hydrocortisone—psoriasis	0.00017	0.00121	CcSEcCtD
Pitavastatin—Asthenia—Mycophenolate mofetil—psoriasis	0.000169	0.00121	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000167	0.00119	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000167	0.00119	CcSEcCtD
Pitavastatin—Pruritus—Mycophenolate mofetil—psoriasis	0.000167	0.00119	CcSEcCtD
Pitavastatin—Arthralgia—Prednisone—psoriasis	0.000166	0.00119	CcSEcCtD
Pitavastatin—Myalgia—Prednisone—psoriasis	0.000166	0.00119	CcSEcCtD
Pitavastatin—Feeling abnormal—Triamcinolone—psoriasis	0.000166	0.00119	CcSEcCtD
Pitavastatin—Insomnia—Betamethasone—psoriasis	0.000166	0.00118	CcSEcCtD
Pitavastatin—Insomnia—Dexamethasone—psoriasis	0.000166	0.00118	CcSEcCtD
Pitavastatin—Diarrhoea—Cyclosporine—psoriasis	0.000165	0.00118	CcSEcCtD
Pitavastatin—Discomfort—Prednisone—psoriasis	0.000164	0.00118	CcSEcCtD
Pitavastatin—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000164	0.01	CbGpPWpGaD
Pitavastatin—Hypersensitivity—Prednisolone—psoriasis	0.000162	0.00116	CcSEcCtD
Pitavastatin—Dyspepsia—Betamethasone—psoriasis	0.000161	0.00115	CcSEcCtD
Pitavastatin—Dyspepsia—Dexamethasone—psoriasis	0.000161	0.00115	CcSEcCtD
Pitavastatin—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000161	0.00115	CcSEcCtD
Pitavastatin—Urticaria—Triamcinolone—psoriasis	0.00016	0.00115	CcSEcCtD
Pitavastatin—Dizziness—Cyclosporine—psoriasis	0.00016	0.00114	CcSEcCtD
Pitavastatin—Back pain—Methotrexate—psoriasis	0.000158	0.00113	CcSEcCtD
Pitavastatin—Hypersensitivity—Hydrocortisone—psoriasis	0.000158	0.00113	CcSEcCtD
Pitavastatin—Fatigue—Betamethasone—psoriasis	0.000158	0.00113	CcSEcCtD
Pitavastatin—Fatigue—Dexamethasone—psoriasis	0.000158	0.00113	CcSEcCtD
Pitavastatin—Dizziness—Mycophenolate mofetil—psoriasis	0.000156	0.00111	CcSEcCtD
Pitavastatin—Asthenia—Hydrocortisone—psoriasis	0.000154	0.0011	CcSEcCtD
Pitavastatin—Rash—Cyclosporine—psoriasis	0.000152	0.00109	CcSEcCtD
Pitavastatin—Dermatitis—Cyclosporine—psoriasis	0.000152	0.00109	CcSEcCtD
Pitavastatin—Pruritus—Hydrocortisone—psoriasis	0.000152	0.00108	CcSEcCtD
Pitavastatin—Ill-defined disorder—Methotrexate—psoriasis	0.000152	0.00108	CcSEcCtD
Pitavastatin—Headache—Cyclosporine—psoriasis	0.000151	0.00108	CcSEcCtD
Pitavastatin—Feeling abnormal—Dexamethasone—psoriasis	0.000151	0.00108	CcSEcCtD
Pitavastatin—Feeling abnormal—Betamethasone—psoriasis	0.000151	0.00108	CcSEcCtD
Pitavastatin—HMGCR—AMPK Signaling—LEP—psoriasis	0.000151	0.00922	CbGpPWpGaD
Pitavastatin—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000151	0.00922	CbGpPWpGaD
Pitavastatin—Gastrointestinal pain—Dexamethasone—psoriasis	0.00015	0.00107	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Betamethasone—psoriasis	0.00015	0.00107	CcSEcCtD
Pitavastatin—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000149	0.00913	CbGpPWpGaD
Pitavastatin—Hypersensitivity—Triamcinolone—psoriasis	0.000149	0.00106	CcSEcCtD
Pitavastatin—Rash—Mycophenolate mofetil—psoriasis	0.000148	0.00106	CcSEcCtD
Pitavastatin—Dermatitis—Mycophenolate mofetil—psoriasis	0.000148	0.00106	CcSEcCtD
Pitavastatin—Headache—Mycophenolate mofetil—psoriasis	0.000147	0.00105	CcSEcCtD
Pitavastatin—Malaise—Methotrexate—psoriasis	0.000147	0.00105	CcSEcCtD
Pitavastatin—Diarrhoea—Hydrocortisone—psoriasis	0.000147	0.00105	CcSEcCtD
Pitavastatin—HMGCR—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000147	0.00896	CbGpPWpGaD
Pitavastatin—Urticaria—Dexamethasone—psoriasis	0.000146	0.00104	CcSEcCtD
Pitavastatin—Urticaria—Betamethasone—psoriasis	0.000146	0.00104	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Prednisone—psoriasis	0.000145	0.00104	CcSEcCtD
Pitavastatin—Dizziness—Prednisolone—psoriasis	0.000145	0.00104	CcSEcCtD
Pitavastatin—Asthenia—Triamcinolone—psoriasis	0.000145	0.00104	CcSEcCtD
Pitavastatin—Abdominal pain—Betamethasone—psoriasis	0.000145	0.00104	CcSEcCtD
Pitavastatin—Abdominal pain—Dexamethasone—psoriasis	0.000145	0.00104	CcSEcCtD
Pitavastatin—Insomnia—Prednisone—psoriasis	0.000144	0.00103	CcSEcCtD
Pitavastatin—Nausea—Cyclosporine—psoriasis	0.000143	0.00102	CcSEcCtD
Pitavastatin—Pruritus—Triamcinolone—psoriasis	0.000143	0.00102	CcSEcCtD
Pitavastatin—Dizziness—Hydrocortisone—psoriasis	0.000142	0.00101	CcSEcCtD
Pitavastatin—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000141	0.00864	CbGpPWpGaD
Pitavastatin—UGT1A3—NRF2 pathway—TGFA—psoriasis	0.000141	0.00863	CbGpPWpGaD
Pitavastatin—Dyspepsia—Prednisone—psoriasis	0.00014	0.001	CcSEcCtD
Pitavastatin—Nausea—Mycophenolate mofetil—psoriasis	0.00014	0.000999	CcSEcCtD
Pitavastatin—Arthralgia—Methotrexate—psoriasis	0.000139	0.000994	CcSEcCtD
Pitavastatin—Myalgia—Methotrexate—psoriasis	0.000139	0.000994	CcSEcCtD
Pitavastatin—Rash—Prednisolone—psoriasis	0.000138	0.00099	CcSEcCtD
Pitavastatin—Dermatitis—Prednisolone—psoriasis	0.000138	0.000989	CcSEcCtD
Pitavastatin—Fatigue—Prednisone—psoriasis	0.000138	0.000983	CcSEcCtD
Pitavastatin—Headache—Prednisolone—psoriasis	0.000138	0.000983	CcSEcCtD
Pitavastatin—Discomfort—Methotrexate—psoriasis	0.000137	0.000982	CcSEcCtD
Pitavastatin—Constipation—Prednisone—psoriasis	0.000136	0.000975	CcSEcCtD
Pitavastatin—Rash—Hydrocortisone—psoriasis	0.000135	0.000967	CcSEcCtD
Pitavastatin—Dermatitis—Hydrocortisone—psoriasis	0.000135	0.000966	CcSEcCtD
Pitavastatin—Confusional state—Methotrexate—psoriasis	0.000134	0.000961	CcSEcCtD
Pitavastatin—Headache—Hydrocortisone—psoriasis	0.000134	0.00096	CcSEcCtD
Pitavastatin—Dizziness—Triamcinolone—psoriasis	0.000134	0.000955	CcSEcCtD
Pitavastatin—Feeling abnormal—Prednisone—psoriasis	0.000131	0.00094	CcSEcCtD
Pitavastatin—Asthenia—Dexamethasone—psoriasis	0.000131	0.00094	CcSEcCtD
Pitavastatin—Asthenia—Betamethasone—psoriasis	0.000131	0.00094	CcSEcCtD
Pitavastatin—HMGCR—SREBP signalling—PPARG—psoriasis	0.000131	0.00803	CbGpPWpGaD
Pitavastatin—Gastrointestinal pain—Prednisone—psoriasis	0.00013	0.000933	CcSEcCtD
Pitavastatin—Nausea—Prednisolone—psoriasis	0.00013	0.000932	CcSEcCtD
Pitavastatin—Pruritus—Betamethasone—psoriasis	0.00013	0.000927	CcSEcCtD
Pitavastatin—Pruritus—Dexamethasone—psoriasis	0.00013	0.000927	CcSEcCtD
Pitavastatin—Nausea—Hydrocortisone—psoriasis	0.000127	0.000911	CcSEcCtD
Pitavastatin—Rash—Triamcinolone—psoriasis	0.000127	0.00091	CcSEcCtD
Pitavastatin—Dermatitis—Triamcinolone—psoriasis	0.000127	0.000909	CcSEcCtD
Pitavastatin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000127	0.00777	CbGpPWpGaD
Pitavastatin—Urticaria—Prednisone—psoriasis	0.000127	0.000906	CcSEcCtD
Pitavastatin—Headache—Triamcinolone—psoriasis	0.000127	0.000904	CcSEcCtD
Pitavastatin—Abdominal pain—Prednisone—psoriasis	0.000126	0.000902	CcSEcCtD
Pitavastatin—Diarrhoea—Dexamethasone—psoriasis	0.000125	0.000896	CcSEcCtD
Pitavastatin—Diarrhoea—Betamethasone—psoriasis	0.000125	0.000896	CcSEcCtD
Pitavastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000122	0.00743	CbGpPWpGaD
Pitavastatin—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000121	0.000868	CcSEcCtD
Pitavastatin—Dizziness—Dexamethasone—psoriasis	0.000121	0.000866	CcSEcCtD
Pitavastatin—Dizziness—Betamethasone—psoriasis	0.000121	0.000866	CcSEcCtD
Pitavastatin—Insomnia—Methotrexate—psoriasis	0.000121	0.000862	CcSEcCtD
Pitavastatin—UGT2B7—NRF2 pathway—TGFA—psoriasis	0.00012	0.00734	CbGpPWpGaD
Pitavastatin—Nausea—Triamcinolone—psoriasis	0.00012	0.000857	CcSEcCtD
Pitavastatin—Hypersensitivity—Prednisone—psoriasis	0.000118	0.00084	CcSEcCtD
Pitavastatin—Dyspepsia—Methotrexate—psoriasis	0.000117	0.000839	CcSEcCtD
Pitavastatin—Rash—Dexamethasone—psoriasis	0.000116	0.000826	CcSEcCtD
Pitavastatin—Rash—Betamethasone—psoriasis	0.000116	0.000826	CcSEcCtD
Pitavastatin—Dermatitis—Dexamethasone—psoriasis	0.000115	0.000825	CcSEcCtD
Pitavastatin—Dermatitis—Betamethasone—psoriasis	0.000115	0.000825	CcSEcCtD
Pitavastatin—Fatigue—Methotrexate—psoriasis	0.000115	0.000822	CcSEcCtD
Pitavastatin—Headache—Betamethasone—psoriasis	0.000115	0.00082	CcSEcCtD
Pitavastatin—Headache—Dexamethasone—psoriasis	0.000115	0.00082	CcSEcCtD
Pitavastatin—Asthenia—Prednisone—psoriasis	0.000114	0.000818	CcSEcCtD
Pitavastatin—Pruritus—Prednisone—psoriasis	0.000113	0.000807	CcSEcCtD
Pitavastatin—SLCO2B1—SLC-mediated transmembrane transport—CP—psoriasis	0.000113	0.00688	CbGpPWpGaD
Pitavastatin—Feeling abnormal—Methotrexate—psoriasis	0.00011	0.000786	CcSEcCtD
Pitavastatin—Diarrhoea—Prednisone—psoriasis	0.000109	0.00078	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Methotrexate—psoriasis	0.000109	0.000779	CcSEcCtD
Pitavastatin—Nausea—Dexamethasone—psoriasis	0.000109	0.000778	CcSEcCtD
Pitavastatin—Nausea—Betamethasone—psoriasis	0.000109	0.000778	CcSEcCtD
Pitavastatin—Urticaria—Methotrexate—psoriasis	0.000106	0.000757	CcSEcCtD
Pitavastatin—Dizziness—Prednisone—psoriasis	0.000106	0.000754	CcSEcCtD
Pitavastatin—Abdominal pain—Methotrexate—psoriasis	0.000105	0.000754	CcSEcCtD
Pitavastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000105	0.00642	CbGpPWpGaD
Pitavastatin—Rash—Prednisone—psoriasis	0.000101	0.000719	CcSEcCtD
Pitavastatin—Dermatitis—Prednisone—psoriasis	0.000101	0.000718	CcSEcCtD
Pitavastatin—Headache—Prednisone—psoriasis	0.0001	0.000715	CcSEcCtD
Pitavastatin—Hypersensitivity—Methotrexate—psoriasis	9.83e-05	0.000702	CcSEcCtD
Pitavastatin—Asthenia—Methotrexate—psoriasis	9.57e-05	0.000684	CcSEcCtD
Pitavastatin—ABCC2—NRF2 pathway—TGFA—psoriasis	9.52e-05	0.00582	CbGpPWpGaD
Pitavastatin—Nausea—Prednisone—psoriasis	9.48e-05	0.000677	CcSEcCtD
Pitavastatin—Pruritus—Methotrexate—psoriasis	9.43e-05	0.000674	CcSEcCtD
Pitavastatin—CYP2C8—Biological oxidations—CYP2S1—psoriasis	9.23e-05	0.00564	CbGpPWpGaD
Pitavastatin—Diarrhoea—Methotrexate—psoriasis	9.12e-05	0.000652	CcSEcCtD
Pitavastatin—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	9.1e-05	0.00556	CbGpPWpGaD
Pitavastatin—HMGCR—PPARA activates gene expression—PPARG—psoriasis	9.05e-05	0.00553	CbGpPWpGaD
Pitavastatin—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	8.86e-05	0.00541	CbGpPWpGaD
Pitavastatin—HMGCR—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	8.85e-05	0.00541	CbGpPWpGaD
Pitavastatin—Dizziness—Methotrexate—psoriasis	8.82e-05	0.00063	CcSEcCtD
Pitavastatin—SLCO1B3—SLC-mediated transmembrane transport—CP—psoriasis	8.79e-05	0.00538	CbGpPWpGaD
Pitavastatin—ALB—Lipoprotein metabolism—APOE—psoriasis	8.66e-05	0.00529	CbGpPWpGaD
Pitavastatin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.58e-05	0.00524	CbGpPWpGaD
Pitavastatin—Rash—Methotrexate—psoriasis	8.41e-05	0.000601	CcSEcCtD
Pitavastatin—Dermatitis—Methotrexate—psoriasis	8.4e-05	0.0006	CcSEcCtD
Pitavastatin—Headache—Methotrexate—psoriasis	8.35e-05	0.000597	CcSEcCtD
Pitavastatin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.01e-05	0.0049	CbGpPWpGaD
Pitavastatin—Nausea—Methotrexate—psoriasis	7.92e-05	0.000566	CcSEcCtD
Pitavastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	7.87e-05	0.00481	CbGpPWpGaD
Pitavastatin—SLC10A1—Metabolism—NDUFA5—psoriasis	7.68e-05	0.00469	CbGpPWpGaD
Pitavastatin—CYP2C9—Biological oxidations—CYP2S1—psoriasis	7.51e-05	0.00459	CbGpPWpGaD
Pitavastatin—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	7.47e-05	0.00457	CbGpPWpGaD
Pitavastatin—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	7.41e-05	0.00453	CbGpPWpGaD
Pitavastatin—SLC10A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.16e-05	0.00438	CbGpPWpGaD
Pitavastatin—ALB—Hemostasis—SERPINB8—psoriasis	7.07e-05	0.00432	CbGpPWpGaD
Pitavastatin—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.96e-05	0.00425	CbGpPWpGaD
Pitavastatin—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	6.85e-05	0.00419	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—HLA-C—psoriasis	6.84e-05	0.00418	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—IL13—psoriasis	6.8e-05	0.00415	CbGpPWpGaD
Pitavastatin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	6.75e-05	0.00412	CbGpPWpGaD
Pitavastatin—SLC10A1—Metabolism—CYP2S1—psoriasis	6.53e-05	0.00399	CbGpPWpGaD
Pitavastatin—HMGCR—Metabolism—NDUFA5—psoriasis	6.26e-05	0.00383	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—IL17A—psoriasis	6.25e-05	0.00382	CbGpPWpGaD
Pitavastatin—HMGCR—AMPK Signaling—TP53—psoriasis	6.15e-05	0.00376	CbGpPWpGaD
Pitavastatin—HMGCR—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	6.1e-05	0.00373	CbGpPWpGaD
Pitavastatin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.98e-05	0.00366	CbGpPWpGaD
Pitavastatin—ALB—Folate Metabolism—CAT—psoriasis	5.93e-05	0.00363	CbGpPWpGaD
Pitavastatin—SLCO1B1—SLC-mediated transmembrane transport—CP—psoriasis	5.91e-05	0.00361	CbGpPWpGaD
Pitavastatin—HMGCR—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.84e-05	0.00357	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—IL12B—psoriasis	5.81e-05	0.00355	CbGpPWpGaD
Pitavastatin—ALB—Vitamin B12 Metabolism—CRP—psoriasis	5.79e-05	0.00354	CbGpPWpGaD
Pitavastatin—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	5.76e-05	0.00352	CbGpPWpGaD
Pitavastatin—SLCO2B1—Transmembrane transport of small molecules—CP—psoriasis	5.72e-05	0.0035	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—HLA-E—psoriasis	5.67e-05	0.00347	CbGpPWpGaD
Pitavastatin—ALB—Vitamin B12 Metabolism—APOE—psoriasis	5.66e-05	0.00346	CbGpPWpGaD
Pitavastatin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.59e-05	0.00341	CbGpPWpGaD
Pitavastatin—SLCO2B1—Transmembrane transport of small molecules—CARM1—psoriasis	5.46e-05	0.00334	CbGpPWpGaD
Pitavastatin—ALB—Folate Metabolism—IL4—psoriasis	5.45e-05	0.00333	CbGpPWpGaD
Pitavastatin—HMGCR—Metabolism—CYP2S1—psoriasis	5.32e-05	0.00325	CbGpPWpGaD
Pitavastatin—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	5.32e-05	0.00325	CbGpPWpGaD
Pitavastatin—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	5.3e-05	0.00324	CbGpPWpGaD
Pitavastatin—UGT1A3—Metabolism—NDUFA5—psoriasis	5.1e-05	0.00312	CbGpPWpGaD
Pitavastatin—HMGCR—Integrated Breast Cancer Pathway—JUN—psoriasis	4.98e-05	0.00304	CbGpPWpGaD
Pitavastatin—SLCO1B3—Metabolism—NDUFA5—psoriasis	4.81e-05	0.00294	CbGpPWpGaD
Pitavastatin—HMGCR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	4.79e-05	0.00293	CbGpPWpGaD
Pitavastatin—ALB—Selenium Micronutrient Network—CAT—psoriasis	4.71e-05	0.00288	CbGpPWpGaD
Pitavastatin—ALB—Folate Metabolism—CRP—psoriasis	4.71e-05	0.00288	CbGpPWpGaD
Pitavastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	4.7e-05	0.00287	CbGpPWpGaD
Pitavastatin—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	4.61e-05	0.00282	CbGpPWpGaD
Pitavastatin—SLCO1B3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.48e-05	0.00274	CbGpPWpGaD
Pitavastatin—SLCO1B3—Transmembrane transport of small molecules—CP—psoriasis	4.47e-05	0.00273	CbGpPWpGaD
Pitavastatin—HMGCR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	4.35e-05	0.00266	CbGpPWpGaD
Pitavastatin—UGT1A3—Metabolism—CYP2S1—psoriasis	4.34e-05	0.00265	CbGpPWpGaD
Pitavastatin—UGT2B7—Metabolism—NDUFA5—psoriasis	4.34e-05	0.00265	CbGpPWpGaD
Pitavastatin—ALB—Folate Metabolism—ICAM1—psoriasis	4.33e-05	0.00265	CbGpPWpGaD
Pitavastatin—SLCO1B3—Transmembrane transport of small molecules—CARM1—psoriasis	4.26e-05	0.00261	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—IL10—psoriasis	4.25e-05	0.0026	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—IL4—psoriasis	4.14e-05	0.00253	CbGpPWpGaD
Pitavastatin—SLCO1B3—Metabolism—CYP2S1—psoriasis	4.09e-05	0.0025	CbGpPWpGaD
Pitavastatin—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	4.05e-05	0.00247	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—HLA-B—psoriasis	4.04e-05	0.00247	CbGpPWpGaD
Pitavastatin—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	4.04e-05	0.00247	CbGpPWpGaD
Pitavastatin—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.03e-05	0.00246	CbGpPWpGaD
Pitavastatin—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	3.76e-05	0.0023	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—HLA-A—psoriasis	3.75e-05	0.00229	CbGpPWpGaD
Pitavastatin—ALB—Selenium Micronutrient Network—CRP—psoriasis	3.74e-05	0.00229	CbGpPWpGaD
Pitavastatin—UGT2B7—Metabolism—CYP2S1—psoriasis	3.69e-05	0.00226	CbGpPWpGaD
Pitavastatin—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	3.44e-05	0.0021	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	3.42e-05	0.00209	CbGpPWpGaD
Pitavastatin—SLC10A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.42e-05	0.00209	CbGpPWpGaD
Pitavastatin—ALB—SLC-mediated transmembrane transport—CP—psoriasis	3.38e-05	0.00206	CbGpPWpGaD
Pitavastatin—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	3.37e-05	0.00206	CbGpPWpGaD
Pitavastatin—ALB—Folate Metabolism—IFNG—psoriasis	3.29e-05	0.00201	CbGpPWpGaD
Pitavastatin—HMGCR—Integrated Breast Cancer Pathway—TP53—psoriasis	3.29e-05	0.00201	CbGpPWpGaD
Pitavastatin—SLCO1B1—Metabolism—NDUFA5—psoriasis	3.23e-05	0.00197	CbGpPWpGaD
Pitavastatin—ABCC2—Transmembrane transport of small molecules—CP—psoriasis	3.2e-05	0.00195	CbGpPWpGaD
Pitavastatin—SLC10A1—Metabolism—CARM1—psoriasis	3.19e-05	0.00195	CbGpPWpGaD
Pitavastatin—ABCC2—Transmembrane transport of small molecules—CARM1—psoriasis	3.05e-05	0.00186	CbGpPWpGaD
Pitavastatin—SLCO1B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.01e-05	0.00184	CbGpPWpGaD
Pitavastatin—SLCO1B1—Transmembrane transport of small molecules—CP—psoriasis	3e-05	0.00184	CbGpPWpGaD
Pitavastatin—ABCG2—Metabolism—NDUFA5—psoriasis	2.99e-05	0.00183	CbGpPWpGaD
Pitavastatin—SLC10A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.98e-05	0.00182	CbGpPWpGaD
Pitavastatin—SLCO1B1—Transmembrane transport of small molecules—CARM1—psoriasis	2.86e-05	0.00175	CbGpPWpGaD
Pitavastatin—HMGCR—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.79e-05	0.0017	CbGpPWpGaD
Pitavastatin—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	2.78e-05	0.0017	CbGpPWpGaD
Pitavastatin—SLCO1B1—Metabolism—CYP2S1—psoriasis	2.75e-05	0.00168	CbGpPWpGaD
Pitavastatin—ALB—Folate Metabolism—NFKB1—psoriasis	2.74e-05	0.00168	CbGpPWpGaD
Pitavastatin—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	2.65e-05	0.00162	CbGpPWpGaD
Pitavastatin—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.62e-05	0.0016	CbGpPWpGaD
Pitavastatin—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2.62e-05	0.0016	CbGpPWpGaD
Pitavastatin—HMGCR—Metabolism—CARM1—psoriasis	2.6e-05	0.00159	CbGpPWpGaD
Pitavastatin—ABCG2—Metabolism—CYP2S1—psoriasis	2.54e-05	0.00155	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—IFNG—psoriasis	2.5e-05	0.00153	CbGpPWpGaD
Pitavastatin—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	2.49e-05	0.00153	CbGpPWpGaD
Pitavastatin—HMGCR—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.43e-05	0.00149	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—CXCL8—psoriasis	2.32e-05	0.00142	CbGpPWpGaD
Pitavastatin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	2.18e-05	0.00133	CbGpPWpGaD
Pitavastatin—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	2.18e-05	0.00133	CbGpPWpGaD
Pitavastatin—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.14e-05	0.00131	CbGpPWpGaD
Pitavastatin—ALB—Platelet degranulation—VEGFA—psoriasis	2.13e-05	0.0013	CbGpPWpGaD
Pitavastatin—ALB—Folate Metabolism—TNF—psoriasis	2.13e-05	0.0013	CbGpPWpGaD
Pitavastatin—UGT1A3—Metabolism—CARM1—psoriasis	2.12e-05	0.0013	CbGpPWpGaD
Pitavastatin—ALB—Vitamin B12 Metabolism—IL6—psoriasis	2.11e-05	0.00129	CbGpPWpGaD
Pitavastatin—ALB—Hemostasis—ITGAL—psoriasis	2.05e-05	0.00125	CbGpPWpGaD
Pitavastatin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.03e-05	0.00124	CbGpPWpGaD
Pitavastatin—SLCO1B3—Metabolism—CARM1—psoriasis	2e-05	0.00122	CbGpPWpGaD
Pitavastatin—SLC10A1—Metabolism—CAT—psoriasis	1.96e-05	0.0012	CbGpPWpGaD
Pitavastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.91e-05	0.00117	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—VEGFA—psoriasis	1.89e-05	0.00115	CbGpPWpGaD
Pitavastatin—ALB—Folate Metabolism—TP53—psoriasis	1.88e-05	0.00115	CbGpPWpGaD
Pitavastatin—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.87e-05	0.00114	CbGpPWpGaD
Pitavastatin—CYP2C8—Metabolism—NDUFA5—psoriasis	1.86e-05	0.00113	CbGpPWpGaD
Pitavastatin—ALB—Metabolism—NDUFA5—psoriasis	1.85e-05	0.00113	CbGpPWpGaD
Pitavastatin—UGT2B7—Metabolism—CARM1—psoriasis	1.8e-05	0.0011	CbGpPWpGaD
Pitavastatin—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.73e-05	0.00106	CbGpPWpGaD
Pitavastatin—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.72e-05	0.00105	CbGpPWpGaD
Pitavastatin—ALB—Folate Metabolism—IL6—psoriasis	1.72e-05	0.00105	CbGpPWpGaD
Pitavastatin—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.72e-05	0.00105	CbGpPWpGaD
Pitavastatin—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.69e-05	0.00104	CbGpPWpGaD
Pitavastatin—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.64e-05	0.001	CbGpPWpGaD
Pitavastatin—ABCB1—Allograft Rejection—TNF—psoriasis	1.62e-05	0.000989	CbGpPWpGaD
Pitavastatin—ABCB1—Metabolism—NDUFA5—psoriasis	1.62e-05	0.000989	CbGpPWpGaD
Pitavastatin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.61e-05	0.000983	CbGpPWpGaD
Pitavastatin—HMGCR—Metabolism—CAT—psoriasis	1.6e-05	0.000977	CbGpPWpGaD
Pitavastatin—CYP2C8—Metabolism—CYP2S1—psoriasis	1.58e-05	0.000965	CbGpPWpGaD
Pitavastatin—ALB—Metabolism—CYP2S1—psoriasis	1.57e-05	0.000959	CbGpPWpGaD
Pitavastatin—SLC10A1—Metabolism—APOE—psoriasis	1.52e-05	0.000931	CbGpPWpGaD
Pitavastatin—CYP2C9—Metabolism—NDUFA5—psoriasis	1.51e-05	0.000924	CbGpPWpGaD
Pitavastatin—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	1.5e-05	0.000919	CbGpPWpGaD
Pitavastatin—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.44e-05	0.00088	CbGpPWpGaD
Pitavastatin—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	1.43e-05	0.000876	CbGpPWpGaD
Pitavastatin—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.41e-05	0.000861	CbGpPWpGaD
Pitavastatin—ABCB1—Metabolism—CYP2S1—psoriasis	1.38e-05	0.000841	CbGpPWpGaD
Pitavastatin—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.37e-05	0.000835	CbGpPWpGaD
Pitavastatin—SLCO1B1—Metabolism—CARM1—psoriasis	1.34e-05	0.00082	CbGpPWpGaD
Pitavastatin—SLC10A1—Metabolism—PPARG—psoriasis	1.33e-05	0.000811	CbGpPWpGaD
Pitavastatin—UGT1A3—Metabolism—CAT—psoriasis	1.3e-05	0.000797	CbGpPWpGaD
Pitavastatin—CYP2C9—Metabolism—CYP2S1—psoriasis	1.28e-05	0.000785	CbGpPWpGaD
Pitavastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.25e-05	0.000767	CbGpPWpGaD
Pitavastatin—HMGCR—Metabolism—APOE—psoriasis	1.24e-05	0.000759	CbGpPWpGaD
Pitavastatin—ABCG2—Metabolism—CARM1—psoriasis	1.24e-05	0.000759	CbGpPWpGaD
Pitavastatin—SLCO1B3—Metabolism—CAT—psoriasis	1.23e-05	0.000751	CbGpPWpGaD
Pitavastatin—UGT2B7—Metabolism—CAT—psoriasis	1.11e-05	0.000677	CbGpPWpGaD
Pitavastatin—HMGCR—Metabolism—PPARG—psoriasis	1.08e-05	0.000661	CbGpPWpGaD
Pitavastatin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.07e-05	0.000652	CbGpPWpGaD
Pitavastatin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.03e-05	0.000627	CbGpPWpGaD
Pitavastatin—UGT1A3—Metabolism—APOE—psoriasis	1.01e-05	0.000619	CbGpPWpGaD
Pitavastatin—SLCO1B3—Metabolism—APOE—psoriasis	9.54e-06	0.000583	CbGpPWpGaD
Pitavastatin—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	9.46e-06	0.000578	CbGpPWpGaD
Pitavastatin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.32e-06	0.000569	CbGpPWpGaD
Pitavastatin—UGT1A3—Metabolism—PPARG—psoriasis	8.82e-06	0.000539	CbGpPWpGaD
Pitavastatin—UGT2B7—Metabolism—APOE—psoriasis	8.61e-06	0.000526	CbGpPWpGaD
Pitavastatin—ALB—Hemostasis—NOS2—psoriasis	8.42e-06	0.000515	CbGpPWpGaD
Pitavastatin—SLCO1B3—Metabolism—PPARG—psoriasis	8.31e-06	0.000508	CbGpPWpGaD
Pitavastatin—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.27e-06	0.000506	CbGpPWpGaD
Pitavastatin—SLCO1B1—Metabolism—CAT—psoriasis	8.25e-06	0.000504	CbGpPWpGaD
Pitavastatin—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.23e-06	0.000503	CbGpPWpGaD
Pitavastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	7.98e-06	0.000488	CbGpPWpGaD
Pitavastatin—CYP2C8—Metabolism—CARM1—psoriasis	7.71e-06	0.000471	CbGpPWpGaD
Pitavastatin—ALB—Metabolism—CARM1—psoriasis	7.67e-06	0.000469	CbGpPWpGaD
Pitavastatin—ABCG2—Metabolism—CAT—psoriasis	7.64e-06	0.000467	CbGpPWpGaD
Pitavastatin—UGT2B7—Metabolism—PPARG—psoriasis	7.5e-06	0.000458	CbGpPWpGaD
Pitavastatin—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.21e-06	0.00044	CbGpPWpGaD
Pitavastatin—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.16e-06	0.000438	CbGpPWpGaD
Pitavastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.04e-06	0.00043	CbGpPWpGaD
Pitavastatin—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.73e-06	0.000412	CbGpPWpGaD
Pitavastatin—ABCB1—Metabolism—CARM1—psoriasis	6.72e-06	0.000411	CbGpPWpGaD
Pitavastatin—SLCO1B1—Metabolism—APOE—psoriasis	6.41e-06	0.000392	CbGpPWpGaD
Pitavastatin—CYP2C9—Metabolism—CARM1—psoriasis	6.27e-06	0.000384	CbGpPWpGaD
Pitavastatin—ABCG2—Metabolism—APOE—psoriasis	5.94e-06	0.000363	CbGpPWpGaD
Pitavastatin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.86e-06	0.000358	CbGpPWpGaD
Pitavastatin—SLCO1B1—Metabolism—PPARG—psoriasis	5.58e-06	0.000341	CbGpPWpGaD
Pitavastatin—ABCG2—Metabolism—PPARG—psoriasis	5.17e-06	0.000316	CbGpPWpGaD
Pitavastatin—ALB—Hemostasis—VEGFA—psoriasis	4.88e-06	0.000298	CbGpPWpGaD
Pitavastatin—CYP2C8—Metabolism—CAT—psoriasis	4.74e-06	0.00029	CbGpPWpGaD
Pitavastatin—ALB—Metabolism—CAT—psoriasis	4.71e-06	0.000288	CbGpPWpGaD
Pitavastatin—ABCB1—Metabolism—CAT—psoriasis	4.13e-06	0.000253	CbGpPWpGaD
Pitavastatin—CYP2C9—Metabolism—CAT—psoriasis	3.86e-06	0.000236	CbGpPWpGaD
Pitavastatin—ALB—Hemostasis—TP53—psoriasis	3.68e-06	0.000225	CbGpPWpGaD
Pitavastatin—CYP2C8—Metabolism—APOE—psoriasis	3.68e-06	0.000225	CbGpPWpGaD
Pitavastatin—ALB—Metabolism—APOE—psoriasis	3.66e-06	0.000224	CbGpPWpGaD
Pitavastatin—ABCB1—Metabolism—APOE—psoriasis	3.21e-06	0.000196	CbGpPWpGaD
Pitavastatin—CYP2C8—Metabolism—PPARG—psoriasis	3.21e-06	0.000196	CbGpPWpGaD
Pitavastatin—ALB—Metabolism—PPARG—psoriasis	3.19e-06	0.000195	CbGpPWpGaD
Pitavastatin—CYP2C9—Metabolism—APOE—psoriasis	3e-06	0.000183	CbGpPWpGaD
Pitavastatin—ABCB1—Metabolism—PPARG—psoriasis	2.8e-06	0.000171	CbGpPWpGaD
Pitavastatin—CYP2C9—Metabolism—PPARG—psoriasis	2.61e-06	0.00016	CbGpPWpGaD
